Amid accusations of inflating sales figures, New Horizon Health (HKG:6606) saw the resignation of Chairman and CEO Zhu Yeqing on Dec. 30, 2024, South China Morning Post reported.
The board also removed him as an executive director. Yao Naxin, a non-executive director, will now serve as board chairman, according to the report.
Earlier in 2024, the early cancer screening company's CFO and auditor also resigned following accusations from a short seller that New Horizon Health had inflated its 2022 sales figures.
Trading in the company's shares has been suspended since March 27, 2024, and will remain so until it meets resumption requirements, the publication said.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.